Ipca Laboratories growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+7.9%+16.0%+23.4%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+14.6%+30.7%+42.6%
+17.5%+37.8%+44.9%
+50.8%+50.2%+9.2%
+54.7%+34.8%+16.1%
+5.2%+5.9%+28.7%
+13.5%+8.6%+30.6%
−13.6%+39.9%+17.2%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

IPCALAB₹1,940.50

Ipca Laboratories Ltd.

· Pharma & Health
₹ CrorePeersTORNTPHARMALKEMJBCHEPHARMABBOTINDIAAJANTPHARMANTHEMGLAXOMEDANTAMcap ₹49,230 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+23.4+16.0+7.9—
EBITDA Growth—+42.6+30.7+14.6—
EBIT Growth—+44.9+37.8+17.5—
Net Income Growth—+9.2+50.2+50.8—
EPS Growth—+16.1+34.8+54.7—
Total Assets Growth—+28.7+5.9+5.2—
Total Equity Growth—+30.6+8.6+13.5—
Cash from Operations Growth—+17.2+39.9-13.6—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.